Immunogenicity of Novel AAV Capsids for Retinal Gene Therapy.

Miranda GehrkeMaria Diedrichs-MöhringJacqueline BogedeinHildegard BüningStylianos MichalakisGerhild Wildner

Published in: Cells (2022)

Due to their enhanced retinal tropism, which allows for dose reduction, the new vector variants are likely to be less immunogenic for gene therapy than the parental AAV2 vector.

Keyphrases

gene therapy
optical coherence tomography
diabetic retinopathy
optic nerve
copy number
gene expression